Predict your next investment

holliseden.com

See what CB Insights has to offer

Partners & Customers

1

About Hollis-Eden Pharmaceuticals

Hollis-Eden Pharmaceuticals Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Hollis-Eden Pharmaceuticals Acquisitions

1 Acquisition

Hollis-Eden Pharmaceuticals acquired 1 company. Their latest acquisition was Aeson Therapeutics on May 24, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/24/2006

$99M

Acquired

Date

5/24/2006

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

Hollis-Eden Pharmaceuticals Partners & Customers

1 Partners and customers

Hollis-Eden Pharmaceuticals has 1 strategic partners and customers. Hollis-Eden Pharmaceuticals recently partnered with Cystic Fibrosis Foundation on December 12, 2007.

Date

Type

Business Partner

Country

News Snippet

Sources

12/20/2007

Partner

United States

Cystic Fibrosis Foundation - 2007 Press Releases Hollis-Eden to Receive $645,000 in Milestone Payments Under Collaboration Agreement. Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects Triolex™ (He3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate.

`` We are pleased that the Cystic Fibrosis Foundation has selected TRIOLEX based on the criteria set forth in our collaboration agreement for developing a novel oral anti-inflammatory drug candidate , '' said Richard B. Hollis , Chairman and CEO , Hollis-Eden Pharmaceuticals , Inc. .

1

Date

12/20/2007

Type

Partner

Business Partner

Country

United States

News Snippet

Cystic Fibrosis Foundation - 2007 Press Releases Hollis-Eden to Receive $645,000 in Milestone Payments Under Collaboration Agreement. Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects Triolex™ (He3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate.

`` We are pleased that the Cystic Fibrosis Foundation has selected TRIOLEX based on the criteria set forth in our collaboration agreement for developing a novel oral anti-inflammatory drug candidate , '' said Richard B. Hollis , Chairman and CEO , Hollis-Eden Pharmaceuticals , Inc. .

Sources

1

Hollis-Eden Pharmaceuticals Team

1 Team Member

Hollis-Eden Pharmaceuticals has 1 team member, including former Founder, Richard Hollis.

Name

Work History

Title

Status

Richard Hollis

Founder

Former

Name

Richard Hollis

Work History

Title

Founder

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.